Gastric mucosal cracked and cobblestone-like changes resulting from proton pump inhibitor use

Digestive Endoscopy

Volumn 29, Issue 3, 2017, Pages 307-313

  Miyamoto, Shuichi ^a   Kato, Mototsugu ^c   Tsuda, Momoko ^a   Matsuda, Kana ^a   Muranaka, Tetsuhito ^a   Abiko, Satoshi ^a   Ono, Masayoshi ^d   Mizushima, Takeshi ^a   Omori, Saori ^e   Yamamoto, Keiko ^a   Mabe, Katsuhiro ^c   Ono, Shoko ^b   Kudo, Takahiko ^a   Shimizu, Yuichi ^b   Sakamoto, Naoya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c National Hospital Organization Hakodate Hospital   (Japan)

^d Hakodate Municipal Hospital   (Japan)

^e Iwamizawa Municipal General Hospital   (Japan)

Author keywords

gastric cobblestone like mucosa; gastric cracked mucosa; helicobacter pylori; parietal cell; proton pump inhibitor

Indexed keywords

GASTRIN; PEPSINOGEN; PROTON PUMP INHIBITOR;

AGED; ARTICLE; CONTROLLED STUDY; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; FLEXIBLE GASTROSCOPE; GASTRIC COBBLESTONE LIKE MUCOSA; GASTRIC CRACKED MUCOSA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; STOMACH BIOPSY; STOMACH FUNDUS GLAND; STOMACH MUCOSA LESION; STOMACH PARIETAL CELL; WHITE LIGHT ENDOSCOPY; BIOPSY; DIGESTIVE TRACT ENDOSCOPY; DRUG EFFECTS; LESIONS AND DEFECTS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; STOMACH DISEASE; STOMACH MUCOSA;

AGED; BIOPSY; DILATATION, PATHOLOGIC; ENDOSCOPY, DIGESTIVE SYSTEM; FEMALE; GASTRIC MUCOSA; HUMANS; MALE; MIDDLE AGED; PARIETAL CELLS, GASTRIC; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; STOMACH DISEASES;

EID: 85010204716     PISSN: 09155635     EISSN: 14431661     Source Type: Journal    
DOI: 10.1111/den.12765     Document Type: Article

References (22)

1. Satoh K, Yoshino J, Akamatsu T et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J. Gastroenterol. 2016; 51: 177–94.
2. Haastrup PF, Paulsen MS, Christensen RD, Sondergaard J, Hansen JM, Jarbol DE. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: A nationwide cohort study of first-time users during a 10-year period. Aliment. Pharmacol. Ther. 2016; 44: 78–87.
3. Boutet R, Wilcock M, MacKenzie I. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly. Aliment. Pharmacol. Ther. 1999; 13: 813–7.
4. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139: 93–101.
5. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 2007; 102: 2047–56; quiz 57.
6. Kumar KR, Iqbal R, Coss E, Park C, Cryer B, Genta RM. Helicobacter gastritis induces changes in the oxyntic mucosa indistinguishable from the effects of proton pump inhibitors. Hum. Pathol. 2013; 44: 2706–10.
7. Hongo M, Fujimoto K., Gastric Polyps Study Group Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: A prospective study in Japan. J. Gastroenterol. 2010; 45: 618–24.
8. Jalving M, Koornstra JJ, Wesseling J, Boezen HM, De Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment. Pharmacol. Ther. 2006; 24: 1341–8.
9. Graham JR. Gastric polyposis: Onset during long-term therapy with omeprazole. Med. J. Aust. 1992; 157: 287–8.
10. Alqutub AN, Masoodi I. A case of gastric polyposis in antral area of stomach following prolonged proton-pump therapy. Ger. Med. Sci. 2010; 2: 1–4.
11. Parks T, Ragland KL, Steiner MA, Subramony C, Bishop P, Nowicki M. Menetrier Mimicker Complicating Ulcerative Colitis: Proton-Pump Inhibitor-Induced Hyperplastic Polyps. J. Pediatr. 2015; 167: 776.e1.
12. Kimura K, Satoh K, Ido K, Taniguchi Y, Takimoto T, Takemoto T. Gastritis in the Japanese stomach. Scand. J. Gastroenterol. Suppl. 1996; 214: 17–20; discussion 21–3.
13. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784–9.
14. Stolte M, Bethke B, Seifert E et al. Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment. Z. Gastroenterol. 1995; 33: 146–9.
15. Declich P, Ambrosiani L, Bellone S et al. Parietal cell hyperplasia with deep cystic dilations: A lesion closely mimicking fundic gland polyps. Am. J. Gastroenterol. 2000; 95: 566–8.
16. Asaka M, Sugiyama T, Nobuta A, Kato M, Takeda H, Graham DY. Atrophic gastritis and intestinal metaplasia in Japan: Results of a large multicenter study. Helicobacter 2001; 6: 294–9.
17. Matsuzaki J, Suzuki H, Minegishi Y et al. Acid suppression by proton pump inhibitors enhances aquaporin-4 and KCNQ1 expression in gastric fundic parietal cells in mouse. Dig. Dis. Sci. 2010; 55: 3339–48.
18. Ishibashi K, Hara S, Kondo S. Aquaporin water channels in mammals. Clin. Exp. Nephrol. 2009; 13: 107–17.
19. Naruki S, Fujino T, Ohnuma S, Endo A, Koizumi H. Histopathologic and Immunohistochemical Characterization of Human Gastric Oxyntic Mucosa with Parietal Cell Protrusions and Investigation into the Association Between Such Mucosal Changes of the Stomach and Use of Proton Pump Inhibitors. J. St. Marianna Univ. 2015; 6: 119–30.
20. Di Mario F, Ingegnoli A, Altavilla N et al. Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels. Fundam. Clin. Pharmacol. 2005; 19: 497–501.
21. Lysy J, Karmeli F, Wengrower D, Rachmilewitz D. Effect of duodenal ulcer healing induced by omeprazole and ranitidine on the generation of gastroduodenal eicosanoids, platelet-activating factor, pepsinogen A, and gastrin in duodenal ulcer patients. Scand. J. Gastroenterol. 1992; 27: 13–19.
22. Stolte M, Bethke B, Ruhl G, Ritter M. Omeprazole-induced pseudohypertrophy of gastric parietal cells. Z. Gastroenterol. 1992; 30: 134–8.